Limits...
A Multicenter, Single-Blind Randomized, Controlled Study of a Volumizing Hyaluronic Acid Filler for Midface Volume Deficit: Patient-Reported Outcomes at 2 Years.

Few J, Cox SE, Paradkar-Mitragotri D, Murphy DK - Aesthet Surg J (2015)

Bottom Line: The effectiveness of Juvéderm Voluma XC was examined from the patient perspective.Increased satisfaction with outer and lower cheek areas and cheek-bone projection and clinically significant improvements in LAFM were noted through month 24.Juvéderm Voluma XC for age-related MVD is effective and well-tolerated from the patient perspective, with results lasting up to 2 years. 4 Therapeutic.

View Article: PubMed Central - PubMed

Affiliation: Dr Few is Clinical Professor of Surgery, Division of Plastic Surgery, University of Chicago Pritzker School of Medicine, Chicago, Illinois. Dr Cox is Assistant Clinical Professor, University of North Carolina, Chapel Hill, North Carolina; and is Supervising Physician, Dermatology Program, Duke University, Durham, North Carolina. Dr Paradkar-Mitragotri was the Manager of Biostatistics at the time of this study and is a former employee of Allergan, Inc., Irvine, California, and Ms Murphy is the Director of Clinical Development Submissions at Allergan, Inc., Irvine, California.

No MeSH data available.


Related in: MedlinePlus

Aesthetic outcomes with Juvéderm Voluma XC for this 48-year-old woman before treatment (A, B), at 6 months (C, D), and at 24 months (E, F) after treatment with 6.3 mL of Juvéderm Voluma XC in the midface.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4482214&req=5

SJV050F5: Aesthetic outcomes with Juvéderm Voluma XC for this 48-year-old woman before treatment (A, B), at 6 months (C, D), and at 24 months (E, F) after treatment with 6.3 mL of Juvéderm Voluma XC in the midface.

Mentions: Representative examples of aesthetic outcomes following treatment with Juvéderm Voluma XC are shown in Figures 5 and 6.Figure 5.


A Multicenter, Single-Blind Randomized, Controlled Study of a Volumizing Hyaluronic Acid Filler for Midface Volume Deficit: Patient-Reported Outcomes at 2 Years.

Few J, Cox SE, Paradkar-Mitragotri D, Murphy DK - Aesthet Surg J (2015)

Aesthetic outcomes with Juvéderm Voluma XC for this 48-year-old woman before treatment (A, B), at 6 months (C, D), and at 24 months (E, F) after treatment with 6.3 mL of Juvéderm Voluma XC in the midface.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4482214&req=5

SJV050F5: Aesthetic outcomes with Juvéderm Voluma XC for this 48-year-old woman before treatment (A, B), at 6 months (C, D), and at 24 months (E, F) after treatment with 6.3 mL of Juvéderm Voluma XC in the midface.
Mentions: Representative examples of aesthetic outcomes following treatment with Juvéderm Voluma XC are shown in Figures 5 and 6.Figure 5.

Bottom Line: The effectiveness of Juvéderm Voluma XC was examined from the patient perspective.Increased satisfaction with outer and lower cheek areas and cheek-bone projection and clinically significant improvements in LAFM were noted through month 24.Juvéderm Voluma XC for age-related MVD is effective and well-tolerated from the patient perspective, with results lasting up to 2 years. 4 Therapeutic.

View Article: PubMed Central - PubMed

Affiliation: Dr Few is Clinical Professor of Surgery, Division of Plastic Surgery, University of Chicago Pritzker School of Medicine, Chicago, Illinois. Dr Cox is Assistant Clinical Professor, University of North Carolina, Chapel Hill, North Carolina; and is Supervising Physician, Dermatology Program, Duke University, Durham, North Carolina. Dr Paradkar-Mitragotri was the Manager of Biostatistics at the time of this study and is a former employee of Allergan, Inc., Irvine, California, and Ms Murphy is the Director of Clinical Development Submissions at Allergan, Inc., Irvine, California.

No MeSH data available.


Related in: MedlinePlus